Lupin Ltd Share Price – NSE  / BSE

Pharmaceuticals, Mid Cap

The inspection was carried out from 25 September 2024 to 04 October 2024, and concluded with five observations.

The company is addressing the observations comprehensively and will respond to the U.S. FDA within the stipulated timeframe.

Mumbai-based Lupin is an innovation-led transnational pharmaceutical company. It develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S, India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

The company’s consolidated net profit jumped 76.01% to Rs 801.31 crore during the quarter as compared with Rs 452.26 crore posted in Q1 FY24. Revenue from operations increased 16.28% YoY to Rs 5,514.34 crore during the quarter.

The scrip had advanced 0.65% to end at Rs 2197.60 on the BSE on Friday.

Powered by Capital Market - Live News

The inspection concluded with 3 observations on both the API and Finished Product sides.

The pharmaceutical major is addressing these observations comprehensively and will respond to the USFDA within the stipulated timeframe.

Mumbai-based Lupin is an innovation-led transnational pharmaceutical company. It develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S, India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

The company’s consolidated net profit jumped 76.01% to Rs 801.31 crore during the quarter as compared with Rs 452.26 crore posted in Q1 FY24. Revenue from operations increased 16.28% YoY to Rs 5,514.34 crore during the quarter.

Shares of Lupin gained 1.56% to end at Rs 2,221.50 on Friday, 27 September 2024.

Powered by Capital Market - Live News

Lupin informed that the U.S. FDA inspected Lupin's Pithampur Unit-1 API and finished product manufacturing facility from 16 September to 27 September 2024. The inspection closed with three observations each on the API and Finished Product side.

Powered by Capital Market - Live News

Lupin has allotted 5,893 equity shares under ESOP on 20 September 2024. Post allotment, the issued and paid-up capital of the Company has been increased to Rs 91,22,86,624 consisting of 45,61,43,312 equity shares of Rs 2/- each.

Powered by Capital Market - Live News